CBRNE - Mustard Agents - Hd, Hn1-3, H Medication

1. Chemical and Biological Weapons Status at a Glance. Arms Control Association. Available at https://www.armscontrol.org/factsheets/cbwprolif. 2022 Mar; Accessed: March 27, 2023.

2. PEO ACWA. https://www.peoacwa.army.mil/2021/09/21/facts-characteristics-of-mustard-blister-agents/. Program Executive Office, Assembled Chemical Weapons Alternatives. Available at https://www.peoacwa.army.mil/2021/09/21/facts-characteristics-of-mustard-blister-agents/. 2021 Sep 21; Accessed: March 27, 2023.

3. Hilmas CJ, Smart J, Hill BA. History of Chemical Warfare. Textbooks of Military Medicine; Medical Aspects of Chemical Warfare. Office of the Surgeon General, United States Army; 2008. 9-76.

4. Hurst CG, Petrali, JP, Barillo DJ, et al. Vesicants. Textbooks of Military Medicine: Medical Aspects of Chemical Warfare. Office of the Surgeon General, United States Army; 2008. 259-309.

5. Alexander, SF. Medical report of the Bari Harbor mustard causalities. Mil Surg. 1947. 101:1-17.

6. Secretary General. United Nations Security Council. Report of the Mission Dispatched by the Secretary-General to Investigate Allegations of the use of Chemical Weapons in the Conflict between the Islamic Republic of Iran and Iraq. United Nations Security Council. Available at https://www.securitycouncilreport.org/atf/cf/%7B65BFCF9B-6D27-4E9C-8CD3-CF6E4FF96FF9%7D/Disarm%20S17911.pdf. 1986 Mar 12; Accessed: March 19, 2023.

7. Technical Secretariat. REPORT OF THE OPCW FACT-FINDING MISSION IN SYRIA REGARDING THE INCIDENTS OF THE ALLEGED USE OF CHEMICALS AS A WEAPON IN MAREA, SYRIAN ARAB REPUBLIC, ON 1 AND 3 SEPTEMBER 201. OPCW. 2022 Jan 24. Available at https://www.opcw.org/sites/default/files/documents/2022/01/s-2017-2022%2B%28e%29.pdf.

8. Sezigen S, Kenar L. Recent sulfur mustard attacks in Middle East and experience of health professionals. Toxicol Lett. 2020 Mar 1. 320:52-57. [QxMD MEDLINE Link].

9. Sezigen S, Ivelik K, Ortatatli M, Almacioglu M, Demirkasimoglu M, Eyison RK, et al. Victims of chemical terrorism, a family of four who were exposed to sulfur mustard. Toxicol Lett. 2019 Mar 15. 303:9-15. [QxMD MEDLINE Link].

10. Sezigen S, Eyison RK, Ortatatli M, Kilic E, Kenar L. Myelosuppression and acute hematological complications of sulfur mustard exposure in victims of chemical terrorism. Toxicol Lett. 2020 Jan. 318:92-98. [QxMD MEDLINE Link].

11. Centers for Disease Control and Prevention (CDC). Notes from the field: Exposures to discarded sulfur mustard munitions - Mid-Atlantic and New England States 2004-2012. MMWR Morb Mortal Wkly Rep. 2013 Apr 26. 62 (16):315-6. [QxMD MEDLINE Link].

12. Newmark J, Langer JM, Capacio B, Barr J, McIntosh RG. Liquid sulfur mustard exposure. Mil Med. 2007 Feb. 172 (2):196-8. [QxMD MEDLINE Link].

13. Ruhl CM, Park SJ, Danisa O, Morgan RF, Papirmeister B, Sidell FR, et al. A serious skin sulfur mustard burn from an artillery shell. J Emerg Med. 1994 Mar-Apr. 12 (2):159-66. [QxMD MEDLINE Link].

14. Vergun D. DOD Approaches Goal of Destroying All Stockpiled Chemical Weapons. DOD News. 2020 Sep 21. Available at https://www.defense.gov/News/News-Stories/Article/Article/2354786/dod-approaches-goal-of-destroying-all-stockpiled-chemical-weapons/.

15. Young RA, Bast CB. Blister agents. Gupta RC. Handbook of Toxicology of Chemical Warfare Agents. Elsevier Inc.; 2020. 149-169.

16. Borak J, Sidell FR. Agents of chemical warfare: sulfur mustard. Ann Emerg Med. 1992 Mar. 21 (3):303-8. [QxMD MEDLINE Link].

17. Papirmeister B, Gross CL, Meier HL, Petrali JP, Johnson JB. Molecular basis for mustard-induced vesication. Fundam Appl Toxicol. 1985 Dec. 5 (6 Pt 2):S134-49. [QxMD MEDLINE Link].

18. Martens ME, Smith WJ. The role of NAD+ depletion in the mechanism of sulfur mustard-induced metabolic injury. Cutan Ocul Toxicol. 2008. 27 (1):41-53. [QxMD MEDLINE Link].

19. Malaviya R, Heck DE, Casillas RE, Laskin JD, Laskin DL. Mustard Vesicants. Lukey BJ, Romano JA, Salem H. Chemical Warfare Agents Biomedical and Psychological Effects, Medical Countermeasures, and Emergency Response. Third. CRC Press Taylor & Francis Group; 2019. 131-144.

20. McNutt PM, Hamilton TA, Lyman ME, Nelson MR. Ocular toxicity of chemical warfare agents. Gupta RC. Handbook of Toxicology of Chemical Warfare Agents. 3rd. Elsevier Inc; 2020. 572-578.

21. Wattana M, Bey T. Mustard gas or sulfur mustard: an old chemical agent as a new terrorist threat. Prehosp Disaster Med. 2009 Jan-Feb. 24 (1):19-29; discussion 30-1. [QxMD MEDLINE Link].

22. Solberg Y, Alcalay M, Belkin M. Ocular injury by mustard gas. Surv Ophthalmol. 1997 May-Jun. 41 (6):461-6. [QxMD MEDLINE Link].

23. Kehe K, Thiermann H, Balszuweit F, Eyer F, Steinritz D, Zilker T. Acute effects of sulfur mustard injury--Munich experiences. Toxicology. 2009 Sep 1. 263 (1):3-8. [QxMD MEDLINE Link].

24. Javadi MA, Yazdani S, Sajjadi H, Jadidi K, Karimian F, Einollahi B, et al. Chronic and delayed-onset mustard gas keratitis: report of 48 patients and review of literature. Ophthalmology. 2005 Apr. 112 (4):617-25. [QxMD MEDLINE Link].

25. Safarinejad MR, Moosavi SA, Montazeri B. Ocular injuries caused by mustard gas: diagnosis, treatment, and medical defense. Mil Med. 2001 Jan. 166 (1):67-70. [QxMD MEDLINE Link].

26. Willems JL. Clinical management of mustard gas casualties. 1989. Available at https://www.opcw.org/sites/default/files/documents/DDG/HSB/medical_defence_CW_course_prereading/Chemical%20management%20of%20mustard%20gas%20casualties.pdf.

27. Dacre JC, Goldman M. Toxicology and pharmacology of the chemical warfare agent sulfur mustard. Pharmacol Rev. 1996 Jun. 48 (2):289-326. [QxMD MEDLINE Link].

28. Sidell FR, Hurst CG. Clinical Considerations in Mustard Poisoning. Somani SM. Chemical Warfare Agents. Academic Press, Inc.; 1992. 51-66.

29. Somani SM. Toxicokinetics and Toxicodynamics of Mustad. Chemical Warfare Agents. Academic Press, Inc; 1992. 13-51.

30. Needham DM, Cohen JA, Barrett AM. The mechanism of damage to the bone marrow in systemic poisoning with mustard gas. Biochem J. 1947. 41 (4):631-9. [QxMD MEDLINE Link].

31. Thomsen AB, Eriksen J, Smidt-Nielsen K. Chronic neuropathic symptoms after exposure to mustard gas: a long-term investigation. J Am Acad Dermatol. 1998 Aug. 39 (2 Pt 1):187-90. [QxMD MEDLINE Link].

32. Capacio BR, Smith R, Gordon RK, Haigh JR, Barr JR, Platoff GE. Medical Diagnostics. Textbooks of Military Medicine Medical Aspects of Chemical Warfare. Office of the Surgeon General at TMM Publications; 2008. 706-728.

33. Rimpel LY, Boehm DE, O’Hern MR, Dashiell TR, Tracy MF. Chemical Defense Equipment. Tuorinsky SD. Textbooks of Military Medicine Medical Aspects of Chemical Warfare. Office of the Surgeon General at TMM Publications; 2008. 559-592.

34. Williams KJ, Stevens J. Field Sensors: Military and Civilian. Lukey BJ, Romano JA, Salem H. Chemical Warfare Agents Biomedical and Psychological Effects, Medical Countermeasures, and Emergency Response. 3rd. CRC Press Taylor & Francis Group; 2019. 519-522.

35. Seto Y. On-site detection of chemical warfare agents. Gupta RC. Handbook of Toxicology of Chemical Warfare Agents. 3rd. Elsevier Inc; 2020. 983-1004.

36. Banks DE. Vesicants. Medical Management of Chemical Casualties Handbook. Office of the Surgeon General, Borden Institute; 2014. 29-64. [Full Text].

37. Ghanei M, Harandi AA. Long term consequences from exposure to sulfur mustard: a review. Inhal Toxicol. 2007 May. 19 (5):451-6. [QxMD MEDLINE Link].

38. Chilcott RP, Lukey BJ, Slife HF, Clarkson ED, Hurst CG, Braue EH. Chemical Warfare Agent Decontamination from Skin. Lukey BJ, Romano JA, Salem H. Chemical Warfare Agents Biomedical and Psychological Effects, Medical Countermeasures, and Emergency Response. 3rd. CRC Press Taylor & Francis Group; 2019. 549-556.

39. OPCW. Practical Guide for Medical Management of Chemical Warfare Casualties. 2019. Available at https://www.opcw.org/sites/default/files/documents/2019/05/Full%20version%202019_Medical%20Guide_WEB.pdf.

40. American Burn Association. Guidelines for Burn Patient Referral. 2022. Available at https://ameriburn.org/wp-content/uploads/2022/11/one-page-guidelines-for-burn-patient-referral-10.pdf.

41. Anderson DR, Holmes WW, Lee RB, Dalal SJ, Hurst CG, Maliner BI, et al. Sulfur mustard-induced neutropenia: treatment with granulocyte colony-stimulating factor. Mil Med. 2006 May. 171 (5):448-53. [QxMD MEDLINE Link].

42. Zafarghandi MR, Soroush MR, Mahmoodi M, Naieni KH, Ardalan A, Dolatyari A, et al. Incidence of cancer in Iranian sulfur mustard exposed veterans: a long-term follow-up cohort study. Cancer Causes Control. 2013 Jan. 24 (1):99-105. [QxMD MEDLINE Link].

43. Darchini-Maragheh E, Balali-Mood M, Malaknezhad M, Mousavi SR. Progressive delayed respiratory complications of sulfur mustard poisoning in 43 Iranian veterans, three decades after exposure. Hum Exp Toxicol. 2018 Feb. 37 (2):175-184. [QxMD MEDLINE Link].

44. Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med. 2003 Nov. 45 (11):1136-43. [QxMD MEDLINE Link].

45. Lagali N, Fagerholm P. Delayed mustard gas keratitis: clinical course and in vivo confocal microscopy findings. Cornea. 2009 May. 28 (4):458-62. [QxMD MEDLINE Link].

46. Balali-Mood M, Hefazi M, Mahmoudi M, Jalali E, Attaran D, Maleki M, et al. Long-term complications of sulphur mustard poisoning in severely intoxicated Iranian veterans. Fundam Clin Pharmacol. 2005 Dec. 19 (6):713-21. [QxMD MEDLINE Link].

47. Panahi Y, Rajaee SM, Sahebkar A. Ocular Effects of Sulfur Mustard and Therapeutic Approaches. J Cell Biochem. 2017 Nov. 118 (11):3549-3560. [QxMD MEDLINE Link].

48. Shohrati M, Peyman M, Peyman A, Davoudi M, Ghanei M. Cutaneous and ocular late complications of sulfur mustard in Iranian veterans. Cutan Ocul Toxicol. 2007. 26 (2):73-81. [QxMD MEDLINE Link].

49. International Agency for Research on Cancer. Sulfur Mustard. IARC Monographs: Chemical Agents and Related Compounds. International Agency for Research on Cancer; 2012. 437-446. [Full Text].

50. Panahi Y, Gholami N, Ghojazadeh M, Moslemi F, Naghavi-Behzad M, Azami-Aghdash S, et al. Complications and Carcinogenic Effects of Mustard Gas--a Systematic Review and Meta-Analysis in Iran. Asian Pac J Cancer Prev. 2015. 16 (17):7567-73. [QxMD MEDLINE Link].

51. Eisenkraft A, Krivoy A, Vidan A, Robenshtok E, Hourvitz A, Dushnitsky T, et al. Phase I study of a topical skin protectant against chemical warfare agents. Mil Med. 2009 Jan. 174 (1):47-52. [QxMD MEDLINE Link].

52. Dachir S, Barness I, Fishbine E, Meshulam J, Sahar R, Eisenkraft A, et al. Dermostyx (IB1) - High efficacy and safe topical skin protectant against percutaneous toxic agents. Chem Biol Interact. 2017 Apr 1. 267:25-32. [QxMD MEDLINE Link].

53. National Institute for Occupational Safety and Health (NIOSH). Sulfur Mustard: Blister Agent. NIOSH. Available at https://www.cdc.gov/niosh/ershdb/emergencyresponsecard_29750008.html. 2011 May 12; Accessed: March 23, 2023.

54. Blister Agents Guide. U.S. Department of Labor: Occupational Safety and Health Administration. Available at https://www.osha.gov/emergency-preparedness/guides/blister-agent. 2023; Accessed: on March 27, 2023.

Christopher P Holstege, MD Professor of Emergency Medicine and Pediatrics, University of Virginia School of Medicine; Chief, Division of Medical Toxicology, Center of Clinical Toxicology; Medical Director, UVAHS Blue Ridge Poison Center; Executive Director, Department of Student Health and Wellness, University of Virginia

Christopher P Holstege, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College Health Association, American College of Emergency Physicians, American College of Medical Toxicology, European Association of Poisons Centres and Clinical Toxicologists, Medical Society of Virginia, Society for Academic Emergency Medicine, Society of Toxicology, Wilderness Medical Society

Disclosure: Nothing to disclose.

Ryan J Cole, MD Fellow, Division of Medical Toxicology, Clinical Instructor, Department of Emergency Medicine, University of Virginia School of Medicine

Ryan J Cole, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American Association of Poison Control Centers, American College of Medical Toxicology

Disclosure: Nothing to disclose.

Paul M Maniscalco, MPA, MS, EMT-P National Director of Emergency Management, Medxcel/Ascension; Maniscalco and Associates, LLC

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Zygmunt F Dembek, PhD, MS, MPH, LHD Associate Professor, Department of Military and Emergency Medicine, Adjunct Assistant Professor, Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences; Senior Research Scientist, Data Science IV, Battelle Memorial Institute, Battelle Connecticut Operations

Zygmunt F Dembek, PhD, MS, MPH, LHD is a member of the following medical societies: American Chemical Society, American Legion, American Public Health Association, The Society of Federal Health Professionals (AMSUS), Council of State and Territorial Epidemiologists, Delta Omega Public Health Honorary Society, New York Academy of Sciences, Polish Legion of American Veterans, Reserve Organization of America, Society of American Federal Medical Laboratory Scientists, Veterans of Foreign Wars

Disclosure: Nothing to disclose.

Daniel J Dire, MD, FACEP, FAAP, FAAEM Professor of Pediatrics and Emergency Medicine, University of Texas Health Science Center at San Antonio, Joe R and Teresa Lozano Long School of Medicine

Daniel J Dire, MD, FACEP, FAAP, FAAEM is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American Academy of Pediatrics, American College of Emergency Physicians, The Society of Federal Health Professionals (AMSUS)

Disclosure: Nothing to disclose.

Fred Henretig, MD Director, Section of Clinical Toxicology, Professor, Medical Director, Delaware Valley Regional Poison Control Center, Departments of Emergency Medicine and Pediatrics, University of Pennsylvania School of Medicine, Children's Hospital

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article